Skip to main content

Table 1 Week 28 (4 weeks post-vaccination) tetanus and pneumococcal antibody immunization responses following 24 weeks of tabalumab treatment

From: BAFF inhibition does not significantly impair immunization responses in patients with rheumatoid arthritis

  120/Q4W 90/Q2W Placebo P value versus placebo
120/Q4W 90/Q2W
Tetanus IgG antibody response n = 21a n = 30a n = 17a   
 Number of patients with ≥4-fold titer increase where baseline titers ≥0.1 IU/mlb (%) 17 (81.0) 13 (43.3) 10 (58.8) 0.167 0.371
 Number of patients with ≥2-fold titer increase where baseline titers ≥0.1 IU/mlb (%) 19 (90.5) 19 (63.3) 10 (58.8) 0.051 0.766
 GMT pre-vaccination baseline (95 % CI) 0.301 (0.182, 0.498) 0.491 (0.280, 0.861) 0.341 (0.163, 0.711)  
 GMT 4 weeks post-vaccination (95 % CI) 3.495 (1.469, 8.315) 2.216 (1.151, 4.267) 1.963 (0.674, 5.713) 0.263c 0.423c
Total pneumococcal IgG antibody response n = 21a n = 31a n = 17a   
 Number of patients with ≥2-fold titer increase where baseline titers ≥4 mg/Lb (%) 15 (71.4) 23 (74.2) 13 (76.5) >0.999 >0.999
 GMT pre-vaccination baseline (95 % CI) 61.78 (46.30, 82.42) 63.77 (50.06, 81.23) 52.53 (36.33, 75.95)  
 GMT post-vaccination (95 % CI) 235.62 (150.97, 367.72) 220.81 (147.19, 331.26) 213.04 (121.83, 372.52) 0.835c 0.563c
  1. CI confidence interval, GMT geometric mean titer, Ig immunoglobulin, 120/Q4W 120 mg tabalumab every 4 weeks, 90/Q2W 90 mg tabalumab every 2 weeks
  2. aThe n values represent the number of patients immunized with vaccine and a baseline and a 28 week antibody titer
  3. bOr a titer of ≥0.2 IU/ml for patients with baseline titers <0.1 IU/ml (tetanus) or ≥6 mg/L for patients with baseline titers <4 mg/L (pneumococcus)
  4. c P value based on change from baseline log transformed data; rather than providing log transformed titers, we present geometric mean titers as this is the standard way to report these data